Lilly's retatrutide meets goals in two Phase 3 obesity trials

July 23, 2026 6:45 AM

Eli Lilly and Company (NYSE: LLY) reported positive topline results from two Phase 3 clinical trials of retatrutide, an investigational ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found